Xeris Biopharma Holdings (XERS) EBT Margin (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly EBT Margin came in at 2.69% in Q1 2026, up 1802.0% YoY from 0.14% in Q1 2025, and down 79.19% on a QoQ basis from 12.91% in Q4 2025.
Xeris Biopharma Holdings (XERS) EBT Margin (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of EBT Margin data on file, last reported at 2.69% in Q1 2026.
- Quarterly EBT Margin rose 1802.0% year-over-year to 2.69% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3.81% (up 2523.0% YoY) and the FY2025 annual result came in at 0.19%, up 2831.0% from the prior year.
- EBT Margin eased to 2.69% in Q1 2026, from 12.91% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 12.91% in Q4 2025 to a low of 154.59% in Q1 2022.
- A 5-year average of 38.6% and a median of 30.7% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin surged 20414 bps — and 2024, when it tumbled 920 bps.
- Tracing XERS's EBT Margin over 5 years: stood at 40.03% in 2022, then grew by 23 bps to 30.7% in 2023, then surged by 72 bps to 8.51% in 2024, then jumped by 252 bps to 12.91% in 2025, then slumped by 79 bps to 2.69% in 2026.
- The last three EBT Margin figures came in at 2.69% (Q1 2026), 12.91% (Q4 2025), and 0.83% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -10.99% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 13.34% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 47.58% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.70% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 16.91% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 4.09% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.48 Bn | 1.36 Bn | 79.59 Mn | -33.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -33.77% |
| Mar 31, 2026 | 2.69% |
| Dec 31, 2025 | 12.91% |
| Sep 30, 2025 | 0.83% |
| Jun 30, 2025 | -2.70% |
| Mar 31, 2025 | -15.34% |
| Dec 31, 2024 | -8.51% |
| Sep 30, 2024 | -35.13% |
| Jun 30, 2024 | -29.66% |
| Mar 31, 2024 | -45.95% |
| Dec 31, 2023 | -30.70% |
| Sep 30, 2023 | -25.93% |
| Jun 30, 2023 | -53.98% |
| Mar 31, 2023 | -50.71% |
| Dec 31, 2022 | -40.03% |
| Sep 30, 2022 | -74.58% |
| Jun 30, 2022 | -104.81% |
| Mar 31, 2022 | -154.59% |
| Dec 31, 2021 | -237.02% |
| Sep 30, 2021 | -235.16% |